{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:26:30Z","timestamp":1778124390454,"version":"3.51.4"},"reference-count":118,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Alzheimer\u2019s disease, a neurodegenerative disease, is a progressive and irreversible disease\nthat has become a global challenge due to its increasing prevalence and absence of available\npotential therapies. Protein misfolding and aggregation are known to be the root of several protein\nneurodegenerative diseases, including Alzheimer\u2019s disease. Protein aggregation is a phenomenon\nwhere misfolded proteins accumulate and clump together intra-or extracellularly. This accumulation\nof misfolded amyloid proteins leads to the formation of plaquesin the neuronal cells, also\nknown as amyloid \u03b2 plaques. The synthesis of amyloid \u03b2 plaques and tau protein aggregation are\nthe hallmarks of Alzheimer\u2019s disease. Potential therapeutics must be developed in conjunction\nwith an understanding of the possible root cause involving complex mechanisms. The development\nof therapeutics that can inhibit protein misfolding and aggregation, involved in the pathogenesis\nof Alzheimer's disease, could be one of the potential solutions to the disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298665247757231020044633","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T11:50:02Z","timestamp":1699617002000},"page":"900-912","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Insight into the Protein Aggregation in Alzheimer\u2019s Disease and its\nInhibition"],"prefix":"10.2174","volume":"30","author":[{"given":"Abdul Basit","family":"Khan","sequence":"first","affiliation":[{"name":"Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan Hasan","family":"Khan","sequence":"additional","affiliation":[{"name":"Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijbiomac.2018.01.099","volume":"112","author":"Khan M.V.","year":"2018","unstructured":"Khan M.V.; Zakariya S.M.; Khan R.H.; Protein folding, misfolding and aggregation: A tale of constructive to destructive assembly. Int J Biol Macromol 2018,112,217-229","journal-title":"Int J Biol Macromol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ijbiomac.2022.01.115","volume":"200","author":"Hassan M.N.","year":"2022","unstructured":"Hassan M.N.; Nabi F.; Khan A.N.; Hussain M.; Siddiqui W.A.; Uversky V.N.; Khan R.H.; The amyloid state of proteins: A boon or bane? Int J Biol Macromol 2022,200,593-617","journal-title":"Int J Biol Macromol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-017-0077-5","volume":"6","author":"Sweeney P.","year":"2017","unstructured":"Sweeney P.; Park H.; Baumann M.; Dunlop J.; Frydman J.; Kopito R.; McCampbell A.; Leblanc G.; Venkateswaran A.; Nurmi A.; Hodgson R.; Protein misfolding in neurodegenerative diseases: Implications and strategies. Transl Neurodegener 2017,6(1),6","journal-title":"Transl Neurodegener"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ijbiomac.2019.05.109","volume":"134","author":"Zaman M.","year":"2019","unstructured":"Zaman M.; Khan A.N.; Uzzaman W.; Zakariya S.M.; Khan R.H.; Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation. Int J Biol Macromol 2019,134,1022-1037","journal-title":"Int J Biol Macromol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/0929866528666211125114421","volume":"29","author":"Zakariya S.M.","year":"2022","unstructured":"Zakariya S.M.; Zehra A.; Khan R.H.; Biophysical insight into protein folding, aggregate formation and its inhibition strategies. Protein Pept Lett 2022,29(1),22-36","journal-title":"Protein Pept Lett"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3389\/fneur.2019.01312","volume":"10","author":"Fan L.","year":"2020","unstructured":"Fan L.; Mao C.; Hu X.; Zhang S.; Yang Z.; Hu Z.; Sun H.; Fan Y.; Dong Y.; Yang J.; Shi C.; Xu Y.; New Insights Into the Pathogenesis of Alzheimer\u2019s Disease. Front Neurol 2020,10,1312","journal-title":"Front Neurol"},{"key":"ref=7","year":"2023","unstructured":"Alzheimer's Disease Fact Sheet. National Insitute on AgingAvailable From: 2023"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"Palmqvist S.","year":"2020","unstructured":"Palmqvist S.; Janelidze S.; Quiroz Y.T.; Zetterberg H.; Lopera F.; Stomrud E.; Su Y.; Chen Y.; Serrano G.E.; Leuzy A.; Mattsson-Carlgren N.; Strandberg O.; Smith R.; Villegas A.; Sepulveda-Falla D.; Chai X.; Proctor N.K.; Beach T.G.; Blennow K.; Dage J.L.; Reiman E.M.; Hansson O.; Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs Other Neurodegenerative Disorders. JAMA 2020,324(8),772-781","journal-title":"JAMA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/IJN.S200490","volume":"14","author":"Tiwari S.","year":"2019","unstructured":"Tiwari S.; Atluri V.; Kaushik A.; Yndart A.; Nair M.; Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomed 2019,14,5541-5554","journal-title":"Int J Nanomed"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-biochem-061516-044518","volume":"86","author":"Hartl F.U.","year":"2017","unstructured":"Hartl F.U.; Protein misfolding diseases. Annu Rev Biochem 2017,86(1),21-26","journal-title":"Annu Rev Biochem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.1925564","volume":"254","author":"Murrell J.","year":"1991","unstructured":"Murrell J.; Farlow M.; Ghetti B.; Benson M.D.; A mutation in the amyloid precursor protein associated with hereditary Alzheimer\u2019s disease. Science 1991,254(5028),97-99","journal-title":"Science"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jocn.2003.12.007","volume":"11","author":"Parihar M.S.","year":"2004","unstructured":"Parihar M.S.; Hemnani T.; Alzheimer\u2019s disease pathogenesis and therapeutic interventions. J Clin Neurosci 2004,11(5),456-467","journal-title":"J Clin Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/aps.2011.14","volume":"32","author":"Nie Q.","year":"2011","unstructured":"Nie Q.; Du X.; Geng M.; Small molecule inhibitors of amyloid \u03b2 peptide aggregation as a potential therapeutic strategy for Alzheimer\u2019s disease. Acta Pharmacol Sin 2011,32(5),545-551","journal-title":"Acta Pharmacol Sin"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"Francis P.T.","year":"1999","unstructured":"Francis P.T.; Palmer A.M.; Snape M.; Wilcock G.K.; The cholinergic hypothesis of Alzheimer\u2019s disease: A review of progress. J Neurol Neurosurg Psychiatry 1999,66(2),137-147","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"no","DOI":"10.1111\/j.1755-5949.2010.00175.x","volume":"16","author":"Martorana A.","year":"2010","unstructured":"Martorana A.; Esposito Z.; Koch G.; Beyond the cholinergic hypothesis: Do current drugs work in Alzheimer\u2019s disease? CNS Neurosci Ther 2010,16(4),no","journal-title":"CNS Neurosci Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/0019-5545.44908","volume":"51","author":"Mohandas E.","year":"2009","unstructured":"Mohandas E.; Rajmohan V.; Raghunath B.; Neurobiology of Alzheimer\u2032s disease. Indian J Psychiatry 2009,51(1),55-61","journal-title":"Indian J Psychiatry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3390\/ijms22031273","volume":"22","author":"Bekdash R.A.","year":"2021","unstructured":"Bekdash R.A.; The Cholinergic system, the adrenergic system and the neuropathology of Alzheimer\u2019s disease. Int J Mol Sci 2021,22(3),1273","journal-title":"Int J Mol Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","volume":"76","author":"Picciotto M.R.","year":"2012","unstructured":"Picciotto M.R.; Higley M.J.; Mineur Y.S.; Acetylcholine as a neuromodulator: Cholinergic signaling shapes nervous system function and behavior. Neuron 2012,76(1),116-129","journal-title":"Neuron"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2222-1808(13)60094-8","volume":"3","author":"Tiwari P.","year":"2013","unstructured":"Tiwari P.; Dwivedi S.; Singh M.P.; Mishra R.; Chandy A.; Basic and modern concepts on cholinergic receptor: A review. Asian Pacific J Trop Dis 2013,3(5),413-420","journal-title":"Asian Pacific J Trop Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/1568015013358536","volume":"1","author":"Tougu V.","year":"2001","unstructured":"Tougu V.; Acetylcholinesterase: Mechanism of Catalysis and Inhibition. Curr Med Chem Cent Nerv Syst Agents 2001,1(2),155-170","journal-title":"Curr Med Chem Cent Nerv Syst Agents"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fnmol.2011.00022","volume":"4","author":"Garc\u00eda-Ayll\u00f3n M.S.","year":"2011","unstructured":"Garc\u00eda-Ayll\u00f3n M.S.; Small D.H.; Avila J.; S\u00e1ez-Valero J.; Revisiting the role of acetylcholinesterase in Alzheimer\u2019s disease: Cross-talk with P-tau and \u03b2-amyloid. Front Mol Neurosci 2011,4,22","journal-title":"Front Mol Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neuropharm.2014.11.018","volume":"96","author":"Lombardo S.","year":"2015","unstructured":"Lombardo S.; Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology 2015,96,255-262","journal-title":"Neuropharmacology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0047-6374(01)00309-8","volume":"122","author":"Talesa V.N.","year":"2001","unstructured":"Talesa V.N.; Acetylcholinesterase in Alzheimer\u2019s disease. Mech Ageing Dev 2001,122(16),1961-1969","journal-title":"Mech Ageing Dev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000100355","volume":"4","author":"Finder V.H.","year":"2007","unstructured":"Finder V.H.; Glockshuber R.; Amyloid-\u03b2 Aggregation. Neurodegener Dis 2007,4(1),13-27","journal-title":"Neurodegener Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e81926","DOI":"10.1371\/journal.pone.0081926","volume":"8","author":"Coburger I.","year":"2013","unstructured":"Coburger I.; Dahms S.O.; Roeser D.; G\u00fchrs K.H.; Hortschansky P.; Than M.E.; Analysis of the overall structure of the multi-domain amyloid precursor protein (APP). PLoS One 2013,8(12),e81926","journal-title":"PLoS One"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pneurobio.2007.02.001","volume":"82","author":"Gralle M.","year":"2007","unstructured":"Gralle M.; Ferreira S.T.; Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. Prog Neurobiol 2007,82(1),11-32","journal-title":"Prog Neurobiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"O\u2019Brien R.J.","year":"2011","unstructured":"O\u2019Brien R.J.; Wong P.C.; Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu Rev Neurosci 2011,34(1),185-204","journal-title":"Annu Rev Neurosci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000369101","volume":"24","author":"Sadigh-Eteghad S.","year":"2015","unstructured":"Sadigh-Eteghad S.; Sabermarouf B.; Majdi A.; Talebi M.; Farhoudi M.; Mahmoudi J.; Amyloid-beta: A crucial factor in Alzheimer\u2019s disease. Med Princ Pract 2015,24(1),1-10","journal-title":"Med Princ Pract"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","volume":"12","author":"Chow V.W.","year":"2010","unstructured":"Chow V.W.; Mattson M.P.; Wong P.C.; Gleichmann M.; An overview of APP processing enzymes and products. Neuromolecular Med 2010,12(1),1-12","journal-title":"Neuromolecular Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/187152708784936626","volume":"7","author":"Venugopal C.","year":"2008","unstructured":"Venugopal C.; Demos C.; Jagannatha Rao K.; Pappolla M.; Sambamurti K.; Beta-secretase: Structure, function, and evolution. CNS Neurol Disord Drug Targets 2008,7(3),278-294","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.tips.2013.01.008","volume":"34","author":"Wang H.","year":"2013","unstructured":"Wang H.; Li R.; Shen Y.; \u03b2-Secretase: Its biology as a therapeutic target in diseases. Trends Pharmacol Sci 2013,34(4),215-225","journal-title":"Trends Pharmacol Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"Murphy M.P.","year":"2010","unstructured":"Murphy M.P.; LeVine H.; Alzheimer\u2019s disease and the amyloid-beta peptide. J Alzheimers Dis 2010,19(1),311-323","journal-title":"J Alzheimers Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fnins.2018.00037","volume":"12","author":"Frozza R.L.","year":"2018","unstructured":"Frozza R.L.; Lourenco M.V.; De Felice F.G.; Challenges for Alzheimer\u2019s disease therapy: Insights from novel mechanisms beyond memory defects. Front Neurosci 2018,12(37),37","journal-title":"Front Neurosci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"Selkoe D.J.","year":"2016","unstructured":"Selkoe D.J.; Hardy J.; The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 2016,8(6),595-608","journal-title":"EMBO Mol Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1007\/s00415-012-6481-y","volume":"259","author":"Karve S.J.","year":"2012","unstructured":"Karve S.J.; Ringman J.M.; Lee A.S.; Juarez K.O.; Mendez M.F.; Comparison of clinical characteristics between familial and non-familial early onset Alzheimer\u2019s disease. J Neurol 2012,259(10),2182-2188","journal-title":"J Neurol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"Bateman R.J.","year":"2010","unstructured":"Bateman R.J.; Aisen P.S.; De Strooper B.; Fox N.C.; Lemere C.A.; Ringman J.M.; Salloway S.; Sperling R.A.; Windisch M.; Xiong C.; Autosomal-dominant Alzheimer\u2019s disease: A review and proposal for the prevention of Alzheimer\u2019s disease. Alzheimers Res Ther 2010,3(1),1","journal-title":"Alzheimers Res Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2323.e1","DOI":"10.1016\/j.neurobiolaging.2010.05.025","volume":"32","author":"Pflanzner T.","year":"2011","unstructured":"Pflanzner T.; Janko M. C.; Andre-Dohmen B.; Reuss S.; Weggen S.; Roebroek A. J.; Kuhlmann C. R.; ALRP1 mediates bidirectional transcytosis of amyloid-\u03b2 across the blood-brain barrier. Neurobiol Aging 2011,32(12),2323.e1-11","journal-title":"Neurobiol Aging"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1016\/B978-141602908-3.50017-0","author":"Jennifer L.","year":"2009","unstructured":"Jennifer L.;  In: Cerebrospinal Fluid in Clinical Practice 2009","journal-title":"In: Cerebrospinal Fluid in Clinical Practice"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00391-7","volume":"15","author":"Guo T.","year":"2020","unstructured":"Guo T.; Zhang D.; Zeng Y.; AMolecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease. Molecular Neurodeg 2020,15(40)","journal-title":"Molecular Neurodeg"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.pharmthera.2007.06.006","volume":"116","author":"Findeis M.A.","year":"2007","unstructured":"Findeis M.A.; The role of amyloid \u03b2 peptide 42 in Alzheimer\u2019s disease. Pharmacol Ther 2007,116(2),266-286","journal-title":"Pharmacol Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1016\/j.bpj.2013.04.056","volume":"104","author":"Ball K.A.","year":"2013","unstructured":"Ball K.A.; Phillips A.H.; Wemmer D.E.; Head-Gordon T.; Differences in \u03b2-strand populations of monomeric A\u03b240 and A\u03b242. Biophys J 2013,104(12),2714-2724","journal-title":"Biophys J"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"Chen Gf.","year":"2017","unstructured":"Chen Gf.; Xu Th.; Yan Y.; Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 2017,38(9),1205-1235","journal-title":"Acta Pharmacol Sin"},{"key":"ref=43","author":"Harper J. D.","year":"1998","unstructured":"Harper J. D.; Mechanistic studies of beta protein amyloid formation in Alzheimer's disease: Identification and characterization of protofibril intermediates Semantic Scholar 1998","journal-title":"Semantic Scholar"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"937133","DOI":"10.3389\/fnmol.2022.937133","volume":"15","author":"Goel P.","year":"2022","unstructured":"Goel P.; Chakrabarti S.; Goel K.; Bhutani K.; Chopra T.; Bali S.; Neuronal cell death mechanisms in Alzheimer\u2019s disease: An insight. Front Mol Neurosci 2022,15,937133","journal-title":"Front Mol Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/ijms23031211","volume":"23","author":"Garc\u00eda-Osta A.","year":"2022","unstructured":"Garc\u00eda-Osta A.; Dong J.; Moreno-Aliaga M.J.; Ramirez M.J.; p27, the cell cycle and Alzheimer\u00b4s disease. Int J Mol Sci 2022,23(3),1211","journal-title":"Int J Mol Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1046\/j.0953-816x.2001.01462.x","volume":"13","author":"Sekine-Aizawa Y.","year":"2001","unstructured":"Sekine-Aizawa Y.; Hama E.; Watanabe K.; Tsubuki S.; Kanai-Azuma M.; Kanai Y.; Arai H.; Aizawa H.; Iwata N.; Saido T.C.; Matrix metalloproteinase (MMP) system in brain: Identification and characterization of brain-specific MMP highly expressed in cerebellum. Eur J Neurosci 2001,13(5),935-948","journal-title":"Eur J Neurosci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature14864","volume":"526","author":"Willem M.","year":"2015","unstructured":"Willem M.; Tahirovic S.; Busche M.A.; Ovsepian S.V.; Chafai M.; Kootar S.; Hornburg D.; Evans L.D.B.; Moore S.; Daria A.; Hampel H.; M\u00fcller V.; Giudici C.; Nuscher B.; Wenninger-Weinzierl A.; Kremmer E.; Heneka M.T.; Thal D.R.; Giedraitis V.; Lannfelt L.; M\u00fcller U.; Livesey F.J.; Meissner F.; Herms J.; Konnerth A.; Marie H.; Haass C.; \u03b7-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 2015,526(7573),443-447","journal-title":"Nature"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnagi.2019.00204","volume":"11","author":"Barbier P.","year":"2019","unstructured":"Barbier P.; Zejneli O.; Martinho M.; Lasorsa A.; Belle V.; Smet-Nocca C.; Tsvetkov P.O.; Devred F.; Landrieu I.; Role of tau as a microtubule-associated protein: Structural and functional aspects. Front Aging Neurosci 2019,11,204 https:\/\/doi.org\/ARTN20410.3389\/fnagi.2019.00204","journal-title":"Front Aging Neurosci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","volume":"84","author":"Avila J.","year":"2004","unstructured":"Avila J.; Lucas J.J.; P\u00e9rez M.; Hern\u00e1ndez F.; Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004,84(2),361-384","journal-title":"Physiol Rev"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2174\/092986708785909111","volume":"15","author":"Gong C.X.","year":"2008","unstructured":"Gong C.X.; Iqbal K.; Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem 2008,15(23),2321-2328","journal-title":"Curr Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.neuron.2016.04.042","volume":"90","author":"Schoch K.M.","year":"2016","unstructured":"Schoch K.M.; DeVos S.L.; Miller R.L.; Chun S.J.; Norrbom M.; Wozniak D.F.; Dawson H.N.; Bennett C.F.; Rigo F.; Miller T.M.; Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 2016,90(5),941-947","journal-title":"Neuron"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1042\/bj3230577","volume":"323","author":"Billingsley M.L.","year":"1997","unstructured":"Billingsley M.L.; Kincaid R.L.; Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997,323(3),577-591","journal-title":"Biochem J"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"108045","DOI":"10.1016\/j.celrep.2020.108045","volume":"32","author":"Briner A.","year":"2020","unstructured":"Briner A.; G\u00f6tz J.; Polanco J.C.; Fyn kinase controls tau aggregation In Vivo. Cell Rep 2020,32(7),108045","journal-title":"Cell Rep"},{"key":"ref=54","first-page":"1141","volume":"58","author":"P\u00eer\u015fcoveanu D.F.V.","year":"2017","unstructured":"P\u00eer\u015fcoveanu D.F.V.; Pirici I.; Tudoric\u0103 V.; B\u0103l\u015feanu T.A.; Albu V.C.; Bondari S.; Bumbea A.M.; P\u00eer\u015fcoveanu M.; Tau protein in neurodegenerative diseases - a review. Rom J Morphol Embryol 2017,58(4),1141-1150","journal-title":"Rom J Morphol Embryol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"Anand R.","year":"2014","unstructured":"Anand R.; Gill K. D.; Mahdi A. A.; Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacol 2014,76(Pt A),27-50","journal-title":"Neuropharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathmechdis-012418-012936","volume":"14","author":"G\u00f6tz J.","year":"2019","unstructured":"G\u00f6tz J.; Halliday G.; Nisbet R.M.; Molecular pathogenesis of the tauopathies. Annu Rev Pathol 2019,14(1),239-261","journal-title":"Annu Rev Pathol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/alzrt214","volume":"5","author":"Pooler A.M.","year":"2013","unstructured":"Pooler A.M.; Polydoro M.; Wegmann S.; Propagation of tau pathology in Alzheimer's disease: Identification of novel therapeutic targets. Alzheimers Res Ther 2013,5(5),49","journal-title":"Alzheimers Res Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fnins.2019.00659","volume":"13","author":"Chen X.Q.","year":"2019","unstructured":"Chen X.Q.; Mobley W.C.; Alzheimer disease pathogenesis: Insights from molecular and cellular biology studies of oligomeric A\u03b2 and tau species. Front Neurosci 2019,13(659),659","journal-title":"Front Neurosci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.arr.2012.06.002","volume":"12","author":"Luan K.","year":"2013","unstructured":"Luan K.; Rosales J.L.; Lee K.Y.; Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation. Ageing Res Rev 2013,12(1),174-181","journal-title":"Ageing Res Rev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/jnen\/nly059","volume":"77","author":"Wu H.Y.","year":"2018","unstructured":"Wu H.Y.; Kuo P.C.; Wang Y.T.; Lin H.T.; Roe A.D.; Wang B.Y.; Han C.L.; Hyman B.T.; Chen Y.J.; Tai H.C.; \u03b2-amyloid induces pathology-related patterns of tau hyperphosphorylation at synaptic terminals. J Neuropathol Exp Neurol 2018,77(9),814-826","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ijbiomac.2020.07.327","volume":"163","author":"Muralidar S.","year":"2020","unstructured":"Muralidar S.; Ambi S.V.; Sekaran S.; Thirumalai D.; Palaniappan B.; Role of tau protein in Alzheimer\u2019s disease: The prime pathological player. Int J Biol Macromol 2020,163,1599-1617","journal-title":"Int J Biol Macromol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3390\/molecules25112716","volume":"25","author":"Barracchia C.G.","year":"2020","unstructured":"Barracchia C.G.; Tira R.; Parolini F.; Munari F.; Bubacco L.; Spyroulias G.A.; D\u2019Onofrio M.; Assfalg M.; Unsaturated fatty acid-induced conformational transitions and aggregation of the repeat domain of tau. Molecules 2020,25(11),2716","journal-title":"Molecules"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"Arboleda-Velasquez J.F.","year":"2019","unstructured":"Arboleda-Velasquez J.F.; Lopera F.; O\u2019Hare M.; Delgado-Tirado S.; Marino C.; Chmielewska N.; Saez-Torres K.L.; Amarnani D.; Schultz A.P.; Sperling R.A.; Leyton-Cifuentes D.; Chen K.; Baena A.; Aguillon D.; Rios-Romenets S.; Giraldo M.; Guzm\u00e1n-V\u00e9lez E.; Norton D.J.; Pardilla-Delgado E.; Artola A.; Sanchez J.S.; Acosta-Uribe J.; Lalli M.; Kosik K.S.; Huentelman M.J.; Zetterberg H.; Blennow K.; Reiman R.A.; Luo J.; Chen Y.; Thiyyagura P.; Su Y.; Jun G.R.; Naymik M.; Gai X.; Bootwalla M.; Ji J.; Shen L.; Miller J.B.; Kim L.A.; Tariot P.N.; Johnson K.A.; Reiman E.M.; Quiroz Y.T.; Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: A case report. Nat Med 2019,25(11),1680-1683","journal-title":"Nat Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/alz.12192","volume":"17","author":"Arnsten A.F.T.","year":"2021","unstructured":"Arnsten A.F.T.; Datta D.; Del Tredici K.; Braak H.; Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer\u2019s disease. Alzheimers Dement 2021,17(1),115-124","journal-title":"Alzheimers Dement"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41593-018-0289-8","volume":"22","author":"Busche M.A.","year":"2019","unstructured":"Busche M.A.; Wegmann S.; Dujardin S.; Tau impairs neural circuits, dominating amyloid-\u03b2 effects, in Alzheimer models in Vivo. Nat Neurosci 2019,22(1),75-64","journal-title":"Nat Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cell.2010.07.032","volume":"142","author":"Haass C.","year":"2010","unstructured":"Haass C.; Mandelkow E.; Fyn-tau-amyloid: A toxic triad. Cell 2010,142(3),356-358","journal-title":"Cell"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40478-020-00976-9","volume":"8","author":"Tang S.J.","year":"2020","unstructured":"Tang S.J.; Fesharaki-Zadeh A.; Takahashi H.; Nies S.H.; Smith L.M.; Luo A.; Chyung A.; Chiasseu M.; Strittmatter S.M.; Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy. Acta Neuropathol Commun 2020,8(1),96","journal-title":"Acta Neuropathol Commun"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s42003-020-01490-3","volume":"4","author":"Cataldi R.","year":"2021","unstructured":"Cataldi R.; Chia S.; Pisani K.; Ruggeri F.S.; Xu C.K.; \u0160neideris T.; Perni M.; Sarwat S.; Joshi P.; Kumita J.R.; Linse S.; Habchi J.; Knowles T.P.J.; Mannini B.; Dobson C.M.; Vendruscolo M.; A dopamine metabolite stabilizes neurotoxic amyloid-\u03b2 oligomers. Commun Biol 2021,4(1),19","journal-title":"Commun Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1021\/cr3000994","volume":"112","author":"Hamley I.W.","year":"2012","unstructured":"Hamley I.W.; The amyloid beta peptide: A chemist\u2019s perspective. Role in Alzheimer\u2019s and fibrillization. Chem Rev 2012,112(10),5147-5192","journal-title":"Chem Rev"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijbiomac.2020.11.192","volume":"167","author":"Ashrafian H.","year":"2021","unstructured":"Ashrafian H.; Zadeh E.H.; Khan R.H.; Review on Alzheimer\u2019s disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol 2021,167,382-394","journal-title":"Int J Biol Macromol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2174\/13816128113199990068","volume":"20","author":"Wang Q.","year":"2014","unstructured":"Wang Q.; Yu X.; Li L.; Zheng J.; Inhibition of amyloid-\u03b2 aggregation in Alzheimer\u2019s disease. Curr Pharm Des 2014,20(8),1223-1243","journal-title":"Curr Pharm Des"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/ijms22031051","volume":"22","author":"Robinson M.","year":"2021","unstructured":"Robinson M.; Lou J.; Mehrazma B.; Rauk A.; Beazely M.; Leonenko Z.; Pseudopeptide amyloid aggregation inhibitors: In silico, single molecule and cell viability studies. Int J Mol Sci 2021,22(3),1051","journal-title":"Int J Mol Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","volume":"83","author":"van Dyck C.H.","year":"2018","unstructured":"van Dyck C.H.; Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: Pitfalls and promise. Biol Psychiatry 2018,83(4),311-319","journal-title":"Biol Psychiatry"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1017\/erm.2016.11","volume":"18","author":"Montoliu-Gaya L.","year":"2016","unstructured":"Montoliu-Gaya L.; Villegas S.; A \u03b2 -Immunotherapeutic strategies: A wide range of approaches for Alzheimer\u2019s disease treatment. Expert Rev Mol Med 2016,18,e13","journal-title":"Expert Rev Mol Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/jnr.22393","volume":"88","author":"Ariga T.","year":"2010","unstructured":"Ariga T.; Miyatake T.; Yu R.K.; Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer\u2019s disease and related disorders: Amyloidogenesis and therapeutic strategies-A review. J Neurosci Res 2010,88(11),2303-2315","journal-title":"J Neurosci Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8501693","volume":"2016","author":"Folch J.","year":"2016","unstructured":"Folch J.; Petrov D.; Ettcheto M.; Abad S.; S\u00e1nchez-L\u00f3pez E.; Garc\u00eda M.L.; Olloquequi J.; Beas-Zarate C.; Auladell C.; Camins A.; Current research therapeutic strategies for Alzheimer\u2019s disease treatment. Neural Plast 2016,2016,1-15","journal-title":"Neural Plast"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jshs.2016.10.004","volume":"5","author":"Vassar R.","year":"2016","unstructured":"Vassar R.; BACE1 inhibition as a therapeutic strategy for Alzheimer\u2019s disease. J Sport Health Sci 2016,5(4),388-390","journal-title":"J Sport Health Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","volume":"33","author":"Das B.","year":"2019","unstructured":"Das B.; Yan R.; A close look at BACE1 inhibitors for Alzheimer\u2019s disease treatment. CNS Drugs 2019,33(3),251-263","journal-title":"CNS Drugs"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3390\/ijms22052341","volume":"22","author":"Lee J.H.","year":"2021","unstructured":"Lee J.H.; Ahn N.H.; Choi S.B.; Kwon Y.; Yang S.H.; Natural products targeting amyloid beta in Alzheimer\u2019s disease. Int J Mol Sci 2021,22(5),2341","journal-title":"Int J Mol Sci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijbiomac.2020.12.030","volume":"171","author":"Zhenxia Z.","year":"2021","unstructured":"Zhenxia Z.; Min L.; Peikui Y.; Zikai C.; Yaqun L.; Junli W.; Fenlian Y.; Yuzhong Z.; Inhibition of tau aggregation and associated cytotoxicity on neuron-like cells by calycosin. Int J Biol Macromol 2021,171,74-81","journal-title":"Int J Biol Macromol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ijbiomac.2020.10.226","volume":"166","author":"Desale S.E.","year":"2021","unstructured":"Desale S.E.; Dubey T.; Chinnathambi S.; \u03b1-Linolenic acid inhibits Tau aggregation and modulates Tau conformation. Int J Biol Macromol 2021,166,687-693","journal-title":"Int J Biol Macromol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijbiomac.2021.02.210","volume":"178","author":"Xiao S.","year":"2021","unstructured":"Xiao S.; Lu Y.; Wu Q.; Yang J.; Chen J.; Zhong S.; Eliezer D.; Tan Q.; Wu C.; Fisetin inhibits tau aggregation by interacting with the protein and preventing the formation of \u03b2-strands. Int J Biol Macromol 2021,178,381-393","journal-title":"Int J Biol Macromol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"8537","DOI":"10.1021\/jf051985c","volume":"53","author":"Kim H.","year":"2005","unstructured":"Kim H.; Park B.S.; Lee K.G.; Choi C.Y.; Jang S.S.; Kim Y.H.; Lee S.E.; Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 2005,53(22),8537-8541","journal-title":"J Agric Food Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuint.2018.05.011","volume":"118","author":"Zhang L.","year":"2018","unstructured":"Zhang L.; Wang H.; Zhou Y.; Zhu Y.; Fei M.; Fisetin alleviates oxidative stress after traumatic brain injury via the Nrf2-ARE pathway. Neurochem Int 2018,118,304-313","journal-title":"Neurochem Int"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fneur.2013.00083","volume":"4","author":"Noble W.","year":"2013","unstructured":"Noble W.; Hanger D.P.; Miller C.C.J.; Lovestone S.; The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 2013,4,83","journal-title":"Front Neurol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fnmol.2014.00046","volume":"7","author":"Llorens-Mart\u00edn M.","year":"2014","unstructured":"Llorens-Mart\u00edn M.; Jurado J.; Hern\u00e1ndez F.; Avila J.; GSK-3\u03b2, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 2014,7,46","journal-title":"Front Mol Neurosci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nbd.2009.04.003","volume":"35","author":"Dewachter I.","year":"2009","unstructured":"Dewachter I.; Ris L.; Jaworski T.; Seymour C.M.; Kremer A.; Borghgraef P.; De Vijver H.; Godaux E.; Van Leuven F.; GSK3\u00df, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at Serine-9. Neurobiol Dis 2009,35(2),193-200","journal-title":"Neurobiol Dis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s41401-020-00565-5","volume":"42","author":"Zhang F.","year":"2021","unstructured":"Zhang F.; Zhong R.; Cheng C.; Li S.; Le W.; New therapeutics beyond amyloid-\u03b2 and tau for the treatment of Alzheimer\u2019s disease. Acta Pharmacol Sin 2021,42(9),1382-1389","journal-title":"Acta Pharmacol Sin"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijbiomac.2021.02.073","volume":"176","author":"Chakraborty S.","year":"2021","unstructured":"Chakraborty S.; Rakshit J.; Bandyopadhyay J.; Basu S.; Multi-target inhibition ability of neohesperidin dictates its neuroprotective activity: Implication in Alzheimer\u2019s disease therapeutics. Int J Biol Macromol 2021,176,315-324","journal-title":"Int J Biol Macromol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"Long J.M.","year":"2019","unstructured":"Long J.M.; Holtzman D.M.; Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019,179(2),312-339","journal-title":"Cell"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4161\/auto.19048","volume":"8","author":"Congdon E.E.","year":"2012","unstructured":"Congdon E.E.; Wu J.W.; Myeku N.; Figueroa Y.H.; Herman M.; Marinec P.S.; Gestwicki J.E.; Dickey C.A.; Yu W.H.; Duff K.E.; Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 2012,8(4),609-622","journal-title":"Autophagy"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","volume":"35","author":"Seren\u00f3 L.","year":"2009","unstructured":"Seren\u00f3 L.; Coma M.; Rodr\u00edguez M.; S\u00e1nchez-Ferrer P.; S\u00e1nchez M.B.; Gich I.; Agull\u00f3 J.M.; P\u00e9rez M.; Avila J.; Guardia-Laguarta C.; Clarim\u00f3n J.; Lle\u00f3 A.; G\u00f3mez-Isla T.; A novel GSK-3\u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009,35(3),359-367","journal-title":"Neurobiol Dis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/17460441.2020.1685977","volume":"15","author":"Noble W.","year":"2020","unstructured":"Noble W.; Jimenez-Sanchez M.; Perez-Nievas B.G.; Hanger D.P.; Considerations for future tau-targeted therapeutics: Can they deliver? Expert Opin Drug Discov 2020,15(3),265-267","journal-title":"Expert Opin Drug Discov"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"Budd Haeberlein S.","year":"2020","unstructured":"Budd Haeberlein S.; Aisen P.; Barkhof F.; Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimer's Dis 2020,9,197-210","journal-title":"J Prev Alzheimer's Dis"},{"key":"ref=95","first-page":"353","volume":"105","author":"Ebell M.H.","year":"2022","unstructured":"Ebell M.H.; Barry H.C.; Why physicians should not prescribe aducanumab for Alzheimer disease. Am Fam Physician 2022,105(4),353-354","journal-title":"Am Fam Physician"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2021.3126","volume":"78","author":"Planche V.","year":"2021","unstructured":"Planche V.; Villain N.; US food and drug administration approval of aducanumab\u2014is amyloid load a valid surrogate end point for Alzheimer disease clinical trials? JAMA Neurol 2021,78(11),1307-1308","journal-title":"JAMA Neurol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1021\/acschemneuro.2c00371","volume":"13","author":"Khan A.N.","year":"2022","unstructured":"Khan A.N.; Nabi F.; Ajmal M.R.; Ali S.M.; Almutairi F.M.; Alalawy A.I.; Khan R.H.; Moxifloxacin disrupts and attenuates A\u03b242 Fibril and oligomer formation: Plausibly repositioning an antibiotic as therapeutic against Alzheimer\u2019s disease. ACS Chem Neurosci 2022,13(16),2529-2539","journal-title":"ACS Chem Neurosci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e12295","DOI":"10.1002\/trc2.12295","volume":"8","author":"Cummings J.","year":"2022","unstructured":"Cummings J.; Lee G.; Nahed P.; Kambar M.E.Z.N.; Zhong K.; Fonseca J.; Taghva K.; Alzheimer\u2019s disease drug development pipeline Alzheimers Dement (N Y) 2022,8(1),e12295","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"113320","DOI":"10.1016\/j.ejmech.2021.113320","volume":"216","author":"Srivastava S.","year":"2021","unstructured":"Srivastava S.; Ahmad R.; Khare S.K.; Alzheimer\u2019s disease and its treatment by different approaches: A review. Eur J Med Chem 2021,216,113320","journal-title":"Eur J Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.nbd.2019.03.028","volume":"129","author":"Sergeant N.","year":"2019","unstructured":"Sergeant N.; Vingtdeux V.; Eddarkaoui S.; Gay M.; Evrard C.; Le Fur N.; Laurent C.; Caillierez R.; Obriot H.; Larchanch\u00e9 P.E.; Farce A.; Coevoet M.; Carato P.; Kouach M.; Descat A.; Dallemagne P.; Bu\u00e9e-Scherrer V.; Blum D.; Hamdane M.; Bu\u00e9e L.; Melnyk P.; New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer\u2019s disease. Neurobiol Dis 2019,129,217-233","journal-title":"Neurobiol Dis"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/17460441.2021.1887132","volume":"16","author":"Imbimbo B.P.","year":"2021","unstructured":"Imbimbo B.P.; Ippati S.; Watling M.; Balducci C.; Accelerating Alzheimer\u2019s disease drug discovery and development: What\u2019s the way forward? Expert Opin Drug Discov 2021,16(7),727-735","journal-title":"Expert Opin Drug Discov"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/ph14020092","volume":"14","author":"Gklinos P.","year":"2021","unstructured":"Gklinos P.; Papadopoulou M.; Stanulovic V.; Mitsikostas D.D.; Papadopoulos D.; Monoclonal antibodies as neurological therapeutics. Pharmaceuticals (Basel) 2021,14(2),92","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"101302","DOI":"10.1016\/j.arr.2021.101302","volume":"67","author":"Kioussis B.","year":"2021","unstructured":"Kioussis B.; Tuttle C.S.L.; Heard D.S.; Kennedy B.K.; Lautenschlager N.T.; Maier A.B.; Targeting impaired nutrient sensing with repurposed therapeutics to prevent or treat age-related cognitive decline and dementia: A systematic review. Ageing Res Rev 2021,67,101302","journal-title":"Ageing Res Rev"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"8208","DOI":"10.3390\/ijms22158208","volume":"22","author":"Yu T.W.","year":"2021","unstructured":"Yu T.W.; Lane H.Y.; Lin C.H.; Novel therapeutic approaches for Alzheimer\u2019s disease: An updated review. Int J Mol Sci 2021,22(15),8208","journal-title":"Int J Mol Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41467-021-27572-2","volume":"13","author":"Yang Y.","year":"2022","unstructured":"Yang Y.; Tapias V.; Acosta D.; Xu H.; Chen H.; Bhawal R.; Anderson E.T.; Ivanova E.; Lin H.; Sagdullaev B.T.; Chen J.; Klein W.L.; Viola K.L.; Gandy S.; Haroutunian V.; Beal M.F.; Eliezer D.; Zhang S.; Gibson G.E.; Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer\u2019s disease. Nat Commun 2022,13(1),159","journal-title":"Nat Commun"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1007\/s00018-017-2542-9","volume":"74","author":"Ma X.","year":"2017","unstructured":"Ma X.; Li H.; He Y.; Hao J.; The emerging link between O-GlcNAcylation and neurological disorders. Cell Mol Life Sci 2017,74(20),3667-3686","journal-title":"Cell Mol Life Sci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/bs.mie.2019.08.004","volume":"626","author":"Dyer R.R.","year":"2019","unstructured":"Dyer R.R.; Ford K.I.; Robinson R.A.S.; The roles of S-nitrosylation and S-glutathionylation in Alzheimer\u2019s disease. Methods Enzymol 2019,626,499-538","journal-title":"Methods Enzymol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"8714","DOI":"10.3390\/ijms23158714","volume":"23","author":"De Plano L.M.","year":"2022","unstructured":"De Plano L.M.; Calabrese G.; Conoci S.; Guglielmino S.P.P.; Oddo S.; Caccamo A.; Applications of CRISPR-Cas9 in Alzheimer\u2019s disease and related disorders. Int J Mol Sci 2022,23(15),8714","journal-title":"Int J Mol Sci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijbiomac.2022.11.031","volume":"223","author":"Khan A. N.","year":"2022","unstructured":"Khan A. N.; Khan R. H.; Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies. Int J Biol Macromol 2022,223(Pt A),143-160","journal-title":"Int J Biol Macromol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"100105","DOI":"10.1074\/jbc.REV120.008207","volume":"296","author":"Lei P.","year":"2020","unstructured":"Lei P.; Ayton S.; Bush A.I.; The essential elements of Alzheimer\u2019s disease. J Biol Chem 2020,296,100105","journal-title":"J Biol Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijbiomac.2019.02.156","volume":"130","author":"Gupta J.","year":"2019","unstructured":"Gupta J.; Fatima M.T.; Islam Z.; Khan R.H.; Uversky V.N.; Salahuddin P.; Nanoparticle formulations in the diagnosis and therapy of Alzheimer\u2019s disease. Int J Biol Macromol 2019,130,515-526","journal-title":"Int J Biol Macromol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"111265","DOI":"10.1016\/j.jinorgbio.2020.111265","volume":"213","author":"Roberts K.F.","year":"2020","unstructured":"Roberts K.F.; Brue C.R.; Preston A.; Baxter D.; Herzog E.; Varelas E.; Meade T.J.; Cobalt(III) Schiff base complexes stabilize non-fibrillar amyloid-\u03b2 aggregates with reduced toxicity. J Inorg Biochem 2020,213,111265","journal-title":"J Inorg Biochem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.3390\/ijms22062888","volume":"22","author":"Windsor P.K.","year":"2021","unstructured":"Windsor P.K.; Plassmeyer S.P.; Mattock D.S.; Bradfield J.C.; Choi E.Y.; Miller B.R.; Han B.H.; Biflavonoid-induced disruption of hydrogen bonds leads to amyloid-\u03b2 disaggregation. Int J Mol Sci 2021,22(6),2888","journal-title":"Int J Mol Sci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.13005\/bpj\/1257","volume":"10","author":"Ganesh R.","year":"2017","unstructured":"Ganesh R.; Kannan I.; Molecular docking study of certain plant alkaloid derivatives as inhibitors of various drug targets of Alzheimer\u2019s disease. Biomed Pharmacol J 2017,10(3),1489-1494","journal-title":"Biomed Pharmacol J"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"104050","DOI":"10.1016\/j.bioorg.2020.104050","volume":"102","author":"Jokar S.","year":"2020","unstructured":"Jokar S.; Erfani M.; Bavi O.; Khazaei S.; Sharifzadeh M.; Hajiramezanali M.; Beiki D.; Shamloo A.; Design of peptide-based inhibitor agent against amyloid-\u03b2 aggregation: Molecular docking, synthesis and in vitro evaluation. Bioorg Chem 2020,102,104050","journal-title":"Bioorg Chem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"Busche M.A.","year":"2020","unstructured":"Busche M.A.; Hyman B.T.; Synergy between amyloid-\u03b2 and tau in Alzheimer's disease. Nat Neurosci 2020,23(10),1183-1193","journal-title":"Nat Neurosci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","volume":"26","author":"Zetterberg H.","year":"2021","unstructured":"Zetterberg H.; Bendlin B.B.; Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry 2021,26(1),296-306","journal-title":"Mol Psychiatry"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13311-021-01146-y","volume":"19","author":"Trejo-Lopez J.A.","year":"2022","unstructured":"Trejo-Lopez J.A.; Yachnis A.T.; Prokop S.; Neuropathology of Alzheimer's disease. Neurotherapeutics 2022,19(1),173-185","journal-title":"Neurotherapeutics"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298665247757231020044633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223435\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298665247757231020044633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T11:29:06Z","timestamp":1706182146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223435\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":118,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298665247757231020044633","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}